Valeant Pharmaceuticals Completes Sale of Certain European Operations to Meda AB
Valeant Pharmaceuticals International announced that it has completed its sale of certain business operations located in Western Europe, Eastern Europe, and certain export markets to Meda AB, pursuant to the Acquisition Agreement entered into by Meda and Valeant on August 4, 2008. Valeant received approximately US$425 million in cash from Meda at closing, which is subject to certain closing adjustments.
Goldman, Sachs & Co. served as financial advisor to Valeant and Skadden, Arps, Slate, Meagher & Flom LLP provided legal advice.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Kawasaki_disease
Tecan launches the HS 400 - a compact 4-slide Hybridization Station

Organic foods may be an unsuspected source of dietary arsenic
